In the pharmaceutical industry, which is a field that is both complex and constantly evolving, the classification of drugs is an extremely important factor that plays a significant role in guiding the development, approval, and application of new medicinal products. The classification of active pharmaceutical ingredients (APIs), which are the fundamental building blocks of drug production, is critical for all parties involved in the drug manufacturing process, including patients, healthcare professionals, and regulators. Sichuan Qingmu Pharmaceutical Co., Ltd., a pioneer in the pharmaceutical industry, provides a fresh viewpoint on the ways in which active pharmaceutical ingredients (APIs) can be classified into a variety of categories. APIs, or active pharmaceutical ingredients, are the biologically active components of pharmaceuticals that trigger the effects that are intended to treat, diagnose, mitigate, cure, or prevent diseases. Taking into account a variety of aspects, including the chemical composition of these substances, the therapeutic effects they have, the applications they have, and the degree of difficulty involved in their synthesis, the classification of these substances is multifaceted. Classification of Chemical MatterThe primary factor that determines how APIs are categorized is their chemical structure. This category encompasses both small molecule drugs, which are typically produced through the process of chemical synthesis, and biologics, which are more complex molecules such as proteins and nucleic acids that are produced through the utilization of living organisms.
Qingmu Pharmaceutical is an industry leader in the production of high-quality small molecule active pharmaceutical ingredients (APIs) thanks to its emphasis on green chemistry and technical platforms such as asymmetric synthesis and enzyme catalysis
Classification Based on Therapeutic Use Another method of categorizing APIs is based on their therapeutic application
Antibiotics are used to treat bacterial infections, oncology active pharmaceutical ingredients (APIs) are used to treat cancer, and cardiovascular drugs are used to treat conditions related to the heart
Both Nilotinib Hydrochloride for Pediatric CML and Apalutamide for Non-Metastatic Castration-Resistant Prostate Cancer are examples of Qingmus's product offerings that demonstrate the company's expertise in the development of active pharmaceutical ingredients (APIs) for specific therapeutic categories
a classification system based on applicationsAnother way to classify active pharmaceutical ingredients (APIs) is according to whether they are designed for use by humans or not
Veterinary active pharmaceutical ingredients (APIs) are utilized in the treatment of animals, whereas human APIs are intended for use in medicines intended for human patients
Qingmu offers a wide variety of products for both the human and veterinary medicine industries
One of these products is oclacitinib, which is a Janus kinase (JAK) inhibitor that has applications in both human and veterinary medicine. Challenges Presented by SynthesisThe manufacturing process of active pharmaceutical ingredients (APIs) can also be used as a classifying basis. Some active pharmaceutical ingredients (APIs) can be synthesized through straightforward chemical reactions, while others require more involved processes that may call for chiral chemistry or more sophisticated purification methods. The Qingmus Research and Development platform is specifically designed to manage complex synthesis procedures, which guarantees the delivery of pharmaceutical products of superior quality. When it comes to the development and delivery of efficient healthcare solutions, the classification of application programming interfaces (APIs) is not merely an academic exercise but rather a crucial foundation. As a result, it guides clinical application, impacts regulatory requirements, and influences the direction that research and development takes. The ability of Qingmu to streamline its production processes, concentrate its research and development efforts, and provide targeted contract manufacturing organization (CMO) services is made possible by the company's understanding of the various categories of active pharmaceutical ingredients (APIs). The commitment of Qingmu Pharmaceuticals to creativity, quality, and environmental responsibility places the company at the forefront of active pharmaceutical ingredient (API) classification and drug development.
Having established a reputation for reliability and expertise over the course of twelve years, the company continues to make a positive impact on the health and well-being of both human and animal populations. They are committed to maintaining their position as a market leader in the API industry, and their participation in events such as CPHI Barcelona 2023 and the upcoming exhibition in Tokyo, Japan, demonstrates their commitment to maintaining that connection with the global pharmaceutical community.
